67392-87-4

  • Product Name:Drospirenone
  • Molecular Formula:C24H30O3
  • Purity:99%
  • Molecular Weight:366.5
InquiryAdd to cart

Product Details;

CasNo: 67392-87-4

Molecular Formula: C24H30O3

Appearance: Off-white crystalline powder

Factory Supply High Purity High Purity Drospirenone 67392-87-4 Efficient Shipping

  • Molecular Formula:C24H30O3
  • Molecular Weight:366.5
  • Appearance/Colour:Off-white crystalline powder 
  • Vapor Pressure:3.07E-12mmHg at 25°C 
  • Melting Point:196-200 °C 
  • Refractive Index:1.61 
  • Boiling Point:552.2 °C at 760 mmHg 
  • Flash Point:241.6 °C 
  • PSA:43.37000 
  • Density:1.26 g/cm3 
  • LogP:4.30590 

Drospirenone(Cas 67392-87-4) Usage

Natural progesterone

Drospirenone is the only progesterone that has the characteristics similar to the natural progesterone currently, its structure is more like that of the natural progesterone compare with the structure of the progesterone contained in the traditional oral contraceptives. Except the effect of anti-androgen, drospirenone has the role of anti-mineralocorticoid which can prevent water and sodium retain in the body. Not only it has the a great effectivenes of contraception, there are also many good impacts on women's health like reducing the acne, making the skin more smooth and controling the weight efficaciously. Information on the use of oral contraceptives, drospirenone, side effects and other information edited by Chemicalbook maggie.

Side effects of human estrogen

Drospirenone is a new synthetic progestin designed to mimic the effects of progesterone, it is the preogesterone which the pharmacological properties is closet to that of the natural progesterone, its also has the advantages of both salt corticosteroids and anti-androgen. As a birth control hormones, Its can reduce the risk of pregnency by imitating progesterone, and increasing the levels of hormones. Therefore drospirenone is promoted as an effective contraception. However, since it has entered the market, drospirenone displays a negative impact on the female estrogen. When two hormones are mixed together, it would bring some bad influence to people. When drospirenone reacts with estrogen, it can cause the blood thicken. It looks not like a big problem, but the blood clotting would lead to the formation of the thrombosis. The gore forming in the veins can impede blood flow or even plug in some vital organs like the heart, brain and lungs etc when it flowing. The thrombosis would Interference the heart from receiving blood which can cause a heart attack. If it affect the blood flow in brain, it would resulting in a stroke. There is a possibility of side effects for any women who take the drospirenone, but the people who is obesity, smoking, depression, and have some diseases like the diabetes and high blood pressure are more likely to form the thrombosis when they take the contraception contained the drospirenone.

Description

Drospirenone is a synthetic progestogen that binds to the progesterone, mineralocorticoid, and androgen receptors with binding affinities of 20, 230, and 65% relative to R5020, aldosterone , and R1881, respectively. In vivo, drospirenone inhibits spontaneous ovulation in rats (ID50s = 0.3-1.0 mg/day) when administered orally or subcutaneously. Drospirenone (0.5 mg/animal) administered six times per day maintains pregnancy in ovariectomized pregnant rats. It reduces serum testosterone (Item Nos. 15645 | ISO60154) and luteinizing hormone in cynomolgus monkeys in a dose-dependent manner. Drospirenone (10 mg/animal per day) also inhibits testosterone-induced growth of the seminal vesicles and prostate in castrated rats. Formulations containing drospirenone have been used as oral contraceptives.

Chemical Properties

Off-White Crystalline Powder

Originator

Schering AG (Germany)

Uses

Synthetic progestogen exhibiting antimineralocorticoid and antiandrogenic activity.

Manufacturing Process

2.75 g of trimethyl sulfoxonium iodide is stirred in 57 ml of dimethyl sulfoxide with 341 mg of 80% sodium hydride oil suspension for 2 h at room temperature. The almost clear solution is combined under nitrogen with 2.0 g of 15α,16α-methylene-3-oxo-4,6-androstadiene-[17(β-1')-spiro- 5']perhydrofuran-2'-one and agitated for 24 h at room temperature. The mixture is then stirred into ice water, the thus-obtained precipitate is filtered off, washed with water, and taken up in methylene chloride. After drying and evaporation, the residue is purified by repeated preparative layer chromatography, thus obtaining 520 mg of 6β,7β,15α,16α-dimethylene-3-oxo- 4-androstene-[17(β-1')-spiro-5']perhydrofuran-2'-one (drospirenone).

Brand name

Yasmin

Therapeutic Function

Aldosterone antagonist

General Description

Drospirenone, 3-oxo-6β,7β:15β,16β-dimethylene-17α-pregn-4-en-21,17-carbolactone,differs structurally from all the other commercially availableprogestins. Its structure is similar to that of spironolactone,an MR antagonist, and it does have antimineralocorticoidactivity as well as progestational activity. It isalso reported to have some antiandrogenic effects. Thespirolactone at C17 and the two cyclopropyl groups at C6-C7 and C15-C16 contribute to these unique actions.Drospirenone is the progestin component in the newer oralcontraceptives, Yasmin and Yaz, and in the HRT product,Angeliq.

Biochem/physiol Actions

Drospirenone is a fourth-generation progestin that has antimineralocorticoid, and antiandrogenic activity in addition to potent progestogenic activity. In two recent studies drospirenone appeared to double the risk of venous thromboembolism compared to levonorgestrel, although other studies found little added risk.

InChI:InChI=1/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

67392-87-4 Relevant articles

Synthetic method of drospirenone

-

, (2021/09/15)

The invention provides a synthetic metho...

A drospirenone and intermediate preparation method (by machine translation)

-

Paragraph 0098-0104, (2019/11/20)

The invention discloses a drospirenone a...

PROCESS FOR THE PREPARATION OF DROSPIRENONE

-

Page/Page column 7; 8; 9; 10, (2014/09/03)

A process is described wherein, by emplo...

PROCESS FOR THE PREPARATION OF DROSPIRENONE

-

Page/Page column 11, (2014/10/29)

A process is disclosed wherein, using ei...

67392-87-4 Process route

6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4,20-diene-21,17-carbolactone

6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4,20-diene-21,17-carbolactone

dihydrospirorenone
90457-65-1,93920-59-3,67372-75-2,67392-87-4

dihydrospirorenone

Conditions
Conditions Yield
With hydrogen; platinum on carbon; In ethyl acetate; for 1h; under 75.0075 Torr; Inert atmosphere;
90%
6β,7β;15β,16β-dimethylene-17β-dihydroxy-17α-(2-ethoxycarbonyl)-ethyl-androst-4-en-3-one

6β,7β;15β,16β-dimethylene-17β-dihydroxy-17α-(2-ethoxycarbonyl)-ethyl-androst-4-en-3-one

dihydrospirorenone
90457-65-1,93920-59-3,67372-75-2,67392-87-4

dihydrospirorenone

Conditions
Conditions Yield
With water; potassium carbonate; In methanol; at 20 ℃; for 0.5h;
66%
With toluene-4-sulfonic acid; In ethyl acetate; at 20 ℃; for 1h;

67392-87-4 Upstream products

  • 82543-18-8
    82543-18-8

    17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-5β-androstane-3β,5,17β-triol

  • 90457-65-1
    90457-65-1

    3-(17β-hydroxy-6β,7β;15β,16β-dimethylene-3-oxo-4-androstene-17β-yl)propionic acid γ-lactone

  • 1015063-83-8
    1015063-83-8

    C25H30O5

  • 67372-65-0
    67372-65-0

    3β-hydorxy-15β,16β-methylene androst-5-ene-17-one

67392-87-4 Downstream products

  • 74220-07-8
    74220-07-8

    Spirorenone

  • 932388-89-1
    932388-89-1

    7β-chloromethyl-15β,16β-methylene-3-oxo-17β-pregn-4-ene-21,17-carbolactone

  • 932388-89-1
    932388-89-1

    7β-chloromethyl-15β,16β-methylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone

Shopping Cart

Clear Inquiry